BioPharmSignal logoBioPharmSignal

Biotech News

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Iovance Biotherapeutics, Inc. (IOVA)Iovance Biotherapeutics, Inc.Commercial

Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for

Related news

KURAKura Oncology2026-09-08 11:00 EST

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

IOVAIovance Biotherapeutics, Inc.2026-09-29 11:00 EST

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

IOVAIovance Biotherapeutics, Inc.2026-09-18 21:10 EST

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

SNDXSyndax Pharmaceuticals2026-09-01 11:00 EST

Syndax Announces Participation in September Investor Conferences

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEGNLegend Biotech Corporation2026-09-15 12:00 EST

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

CRSPCRISPR Therapeutics2026-10-02 14:15 EST

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

SANASana Biotechnology2026-09-01 20:05 EST

Sana Biotechnology to Present at September 2026 Investor Conferences

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

View all latest news

Iovance Biotherapeutics, Inc.

Tumor-Infiltrating Lymphocyte Therapy Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion. Amtagvi Amtagvi, or lifileucel, is approved in the United States for selected patients...

Recent company news

IOVAIovance Biotherapeutics, Inc.2026-10-01 11:00 EST

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

IOVAIovance Biotherapeutics, Inc.2026-09-29 11:00 EST

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

IOVAIovance Biotherapeutics, Inc.2026-09-18 21:10 EST

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVAIovance Biotherapeutics, Inc.2026-09-04 12:00 EST

Iovance Biotherapeutics to Present at Upcoming Conferences

IOVAIovance Biotherapeutics, Inc.2026-08-21 21:15 EST

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Stock data

Close
14.23 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States